Actively Recruiting Clinical Trials for Oral, Head, and Neck Cancers

Get Permission

THIS CLINICAL TRIALS Resource Guide includes actively recruiting clinical studies that focus on different techniques; treatments; and technology for oral, head, and neck cancers. More specifically, these trials are evaluating different drug combination regimens for both tumor treatment and pain management, multiple kinds of radiation therapies, and novel surgical technologies.

Both of the studies described here can be found on the National Institutes of Health website at


Study Title: Evaluation of Fluorescence Imaging in Head and Neck Cancer

Study Type: Interventional/single-group assignment

Study Sponsor and Collaborators: Washington University School of Medicine

Purpose: To develop hands-free goggle technology that can visualize white light and near-infrared light simultaneously to improve the safety and accuracy of sentinel lymph node biopsies for head and neck mucosal and cutaneous tumors

Primary Outcome Measures: Feasibility of using a novel fluorescence imaging device to detect a sentinel lymph node as measured by the ability of the imaging device to assist the surgeon in identifying the sentinel lymph node during a standard biopsy procedure [time frame: up to 1 week after surgery]. Feasibility will be assessed in terms of the percentage of patients enrolled for whom peritumoral injection with indocyanine green is performed successfully.

Principal Investigator: Ryan Jackson, MD, Washington University School of Medicine; contact (314) 362-0365, Identifier: NCT03297957


Study Title: Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers

Study Type: Interventional/single-group assignment

Study Sponsor and Collaborators: University of Washington

Purpose: To study how well nivolumab and ipilimumab work when given together with stereotactic body radiation therapy, and the side effects thereof, in treating patients with salivary gland cancers

Primary Outcome Measures: Incidence of adverse events [time frame: up to 100 days posttreatment]

Principal Investigator: Cristina Rodriguez, MD, Fred Hutchinson Cancer Research Center; contact Susan Masterson, (206) 606-7445,

Editor’s Note: The clinical trials presented here do not represent all the trials listed on For the complete list, go to ■